PDCD1 and melanoma: In a phase I/II study assessing the tolerability of relatlimab in combination with nivolumab, the objective response rate (ORR) was observed in 11.5% of patients with advanced melanoma whose tumors had progressed on previous anti-PD-1 or anti-PD-L1 immunotherapy (58).